Past Speakers

Many of the most dynamic CEO's in the region have spoken at previous symposiums.  Past keynote speakers who have shared their perspectives on the industry's successes and challenges have included:

• Frank Baldino, Jr., Ph.D., chairman & CEO, Cephalon, Inc.
• Boomer Esiason, co-chair, The Boomer Esiason Foundation
• Fred Hassan, senior advisor, Warbug Pincus LLC, former chairman & CEO, Schering-Plough Corporation
• David Holveck, president and CEO, Endo Pharmaceuticals
• Robert Hugin, president and COO, Celgene Corporation
• G. Kelly Martin,president and CEO, Elan Corporation, plc
• Margaret G. McGlynn, R.Ph., president, vaccines and infectious disease, Merck & Co., Inc.
• Joseph Scodari, former chairman, worldwide pharmaceuticals, Johnson & Johnson
• Harlan F. Weisman, M.D., chief science and technology officer, medical devices & diagnostics, Johnson & Johnson

Speakers from Biotech 2009 included: 

• Gwilym Attwell, principal, Fish & Richardson P.C.
• Stephen Badylak, D.V.M., Ph.D., M.D., deputy director of the McGowan Institute for Regenerative Medicine, University of Pittsburgh
• William "Chip" Baird, CFO, PTC Therapeutics, Inc.
• Stephanie Baldwin, principal, Strategic Corporate Advocates, LLC
• Samina Bari, senior director, communications, Ikaria 
• Norman Baylor, Ph.D., director of the Office of Vaccines Research and Review (OVRR), Food and Drug Administration, Center for Biologics Evaluation and Research
• Ronald Berg, CEO, RadPharm, Inc.   
• Bruce Bloom, DDS, J.D., president and CSO, Partnership for Cures
• Todd Brady, M.D., Ph.D., principal, Domain Associates, LLC
• Keith Brownlie, CPA, partner and Metro New York Life Science Industry Leader, Ernst & Young
• James Burnes, managing director, healthcare investment banking, Oppenheimer & Co. Inc.
• Peter Butch, III, member, intellectual property practice, Fox Rothschild LLP
• Tauseef Butt, Ph.D., president and CEO, LifeSensors, Inc.
• Steven Campanini, health care communications consultant
• Arthur Caplan, Ph.D., Sidney D. Caplan professor of bioethics, Emanuel & Robert Hart director, Center for Bioethics, University of Pennsylvania School of Medicine
• Christopher Cashman, president & CEO, Protez Pharmaceuticals
• Patrick Caubel, M.D., Ph.D., vice president, global head pharmacovigilance and medical safety analysis, sanofi pasteur
• Geert Cauwenbergh, Ph.D., chairman & CEO, RHEI Pharmaceuticals and founder & CEO, Phases123
• Alex Chang, Ph.D., director of business development, Samyang Research Corporation
• James Datin, executive vice president & managing director, Life Sciences Group, Safeguard Scientifics, Inc.
• Rodney Dausch, vice president of project management & CFO, Morphotek, Inc.
• Blaine Davis, vice president, corporate affairs, Endo Pharmaceuticals
• Manya Deehr, chief legal officer and corporate secretary, Eurand
• Brent Del Monte, vice president, federal government relations and lead lobbyist, Biotechnology Industry Organization (BIO)
• James Dentzer, CFO, Amicus Therapeutics
• Michael Detke, M.D., Ph.D., chief medical officer, MedAvante & director, MedAvante Research Institute, clinical associate professor of psychiatry, Indiana University School of Medicine, research affiliate, McLean Hospital, and research associate, Harvard Medical School
• Diane DiResta, founder, DiResta Communications, Inc.
• Andy Drechsler, CFO, VaxInnate
• Steven Elek, III, partner, transaction services, PricewaterhouseCoopers
• Mike Erickson, Ph.D., associate partner, McKinsey & Company
• Marni Falk, M.D., assistant professor of pediatrics, The Children’s Hospital of Philadelphia
• Michael Fleming, senior director, new media, GlaxoSmithKline
• John Fraher, chief commercial officer, Eurand
• Bruce Freundlich, M.D., vice president, global medical affairs, Pfizer Inc.
• Gloria Fuentes, J.D., Ph.D., legal director, patents, Schering-Plough Corporation
• Doug Gessl, CFO, Ception Therapeutics, Inc.
• Paul Gilbert, CEO, MedAvante, Inc.
• John Gill, president, CEO, director & founder, TetraLogic Pharmaceuticals
• Robert Glassman, M.D., private equity partner, OrbiMed Advisors, LLC
• Keith Goldan, CPA, MBA, vice president & CFO, NuPathe Inc.
• Ulrich Grau, Ph.D., president and CEO, Lux Biosciences, Inc.
• Valentin Gribkoff, Ph.D., CSO & senior vice president, discovery research, Knopp Neurosciences, Inc.
• Gary Grover, Ph.D., executive director, pharmacology, Eurofins – Product Safety Labs
• Joseph Hammang, Ph.D., senior director of worldwide science policy, Pfizer Inc. 
• Juan Harrison, vice president, Takeda Research Investment, Inc.
• Kevin Harter, executive chairman, Saladax Biomedical, Inc.
• Thomas Hess, CPA, senior vice president, finance and CFO, Yaupon Therapeutics Inc.
• Jane Hollingsworth, CEO, NuPathe Inc.
• Jane Horvath, senior director, federal policy and federal relations, Merck & Co., Inc.
• Robert Hrubiec, Ph.D., J.D., vice president, intellectual property, Cephalon, Inc.
• Nancy Kavanaugh, Ph.D., senior director, regulatory affairs, MedImmune, LLC
• David King, Esq., venture partner, Quaker BioVentures
• Thomas Koncsics, partner, KPMG LLP
• Cynthia Lander, Ph.D., partner, Nascent Enterprises, LLC
• Angela Larson, founder, Larson Pharma Consult, LLC
• Frank LaSaracina, CPA, principal, Southpoint Associates LLC
• Mark Leahey, president & CEO, Medical Device Manufacturers Association
• Brian Lenz, CPA, CFO, Arno Therapeutics, Inc.
• Brian Leuthner, president & CEO, Edge Therapeutics, Inc.
• Lih-Ling Lin, Ph.D., research fellow, inflammation signaling, inflammation & immunology, Pfizer Inc.
• Douglas Long, vice president of industry relations, IMS Health, Inc.
• Andrew Loxley, Ph.D., director new technologies, Particle Sciences Inc.
• Maria Maccecchini, Ph.D., president & CEO, QR Pharma, Inc.
• R. Loch Macdonald, M.D., Ph.D., co-founder and CSO, Edge Therapeutics, Inc.
• Joseph Mahady, senior vice president, Wyeth, president, Wyeth Pharmaceuticals (retired)
• John Maki, president & CEO, Vicus Therapeutics
• James Marino, Esq., partner, Dechert LLP
• James Matthews, Ph.D., senior director health & science policy, sanofi pasteur
• Emily Mendell, vice president, strategic affairs, National Venture Capital Association
• Vincent Milano, president and CEO, ViroPharma Incorporated
• Dean Miller, managing partner, Novitas Capital
• Joshua Muntner, managing director, ThinkEquity, LLC
• Ramachandran Murali, Ph.D., associate professor, department of pathology and laboratory medicine, University of Pennsylvania
• Pam Murphy, vice president investor relations & corporate communications, Incyte Corporation
• Francois Nader, M.D., president & CEO, NPS Pharmaceuticals, Inc.
• Bob Pearson, chief technology & media officer, WeissComm Group
• Stuart Peltz, Ph.D, president & CEO, PTC Therapeutics Inc.
• Thomas Penn, senior partner, MVP Capital Partners
• John Pennett, CPA, partner & director, life sciences practice, Amper, Politziner & Mattia, LLP
• Sherrie Preische, Ph.D., senior director, business development, Genmab
• Peter Reczek, Ph.D., executive director, New Jersey Commission on Science & Technology
• Martin Reeves, vice president, business development and strategic planning, Cephalon, Inc.
• H. Joseph Reiser, Ph.D., president & CEO, CureDM Inc.
• John Rothman, Ph.D., executive vice president, science & operations, Advaxis
• Jason Rubin, president, The Redstone Group, LLC
• James Sapirstein, R.Ph., MBA, president & CEO, Tobira Therapeutics, Inc.
• Zev Scherl, general partner, NewSpring Capital
• Barbara Schilberg, managing director & CEO, BioAdvance
• J. Howison Schroeder, president and CEO, Neuro Kinetics, Inc.
• Marvin Schwalb, Ph.D., vice president & CSO, CGC Genetics, Inc.
• Evonne Sepsis, managing director and founder, ESC Advisors
• Nancy Shute, contributing editor, U.S. News and World Report
• Neal Simon, Ph.D., CEO, Azevan Pharmaceuticals, Inc.
• Daniel Skovronsky, M.D., Ph.D., CEO, Avid Radiopharmaceuticals, Inc.
• Gary Slatko, M.D., MBA, chief medical officer, ParagonRx, LLC
• Gary Smith, founder and managing partner, Enterprise Law Associates
• Joanne Soslow, partner, Morgan, Lewis & Bockius LLP
• William Stern, Ph.D., group leader, formulation development, Unigene Laboratories, Inc.
• Jack Stover, executive chairman, Targeted Nano Therapeutics
• Stephen Tang, Ph.D., president & CEO, University City Science Center
• Kevin Taylor, vice president, business development, Adolor Corporation
• Peter Tolias, Ph.D., professor and executive director, Institute of Genomic Medicine, UMDNJ – New Jersey Medical School
• Paul Touhey, president & CEO, Fujirebio Diagnostics, Inc.
• Luk Vandenberghe, Ph.D., director, translation research, gene therapy program, University of Pennsylvania
• Robert Ward, vice president, alliance management and corporate development, NPS Pharmaceuticals
• Sheryl Williams, vice president, corporate & public affairs, Cephalon, Inc.
• Clarence Young, M.D., vice president, drug development & chief medical officer, Protez Pharmaceuticals, Inc.
• Wise Young, M.D., Ph.D., founding director, W.M. Keck Center for Collaborative Neuroscience, Rutgers University